IMU (ASX) Ann: Imugene Capital Raising Presentation

Originally posted by Taureanbull: ↑

Jov88, Another good post. However the common myth here is that the dilution is 20%. If we break down the numbers I get a Dilution of 6.5%. At present there are roughly 6.4bn shares on issue. The Instos and Directors get $35m worth of share at .084 cents. That’s 6.5%. The SPP give most shareholders especially small shareholders the opportunity to buy $30,000 at ~.o84. So roughly another 6.5%. Is that DILUTION or is it topping up capital as a business owner/ part business owner to buy in new assets ? I would definitely say this is increasing a shareholders investment in an increasingly bigger and better company.

So today any shareholder can buy shares at .079. The new IMUOE are convertible before Aug 2026 at .115 cents. Or shareholders can buy shares right now on the open market for .079 cents. I don’t see any dilution or massive discount there. In fact that’s probably fairly priced.

For all the blood curdling screams and plans of revenge coming from the keyboard warriors and armchair experts out there, who have absolutely NO EXPERIENCE in running a start-up , running a Biotech Company. Little to NO experience investing let alone investing in the most difficult sector the stock market , they should take the time to consider what LC has said in the announcements.

This acquisition, is an ORPHAN DRUG which comes with the best DATA PACKAGE of any Allogenic CD19 Directed CarT therapy in the world. It’s passed it’s safety trial with 84 patients. With a very high ORR of 84%. all at the cost of a 6.5% dilution

This amazing deal comes with the highly specialised factory and team to produce the Therapy. This is a requirement that satisfies the FDA requirements to get Marketing Approval. That’s a big item ticked off.

Now IMU owns the whole game. The biggest game in town ONCOLOGY . That’s Solid tumors and liquid tumors. All in one UNIVERSAL VACCINE. Not only that, there’s more. In JUNE a meeting was held with the FDA about progressing this drug to a Registrational trial starting in 2024. What we don’t know at this point , is who was there. Was LC or Dr Jakob DuPont invited along to this meeting? I suspect they were.

What is our next move ? We probably should expect a variation to our Oncarlytics FDA IND to include an arm that uses our new CarT. Now that we have both CF33 Oncovirus and CarT therapies that have passed safety trials we are ready to head for Breakthrough Approval for our Universal Vaccine.

This is so breathtaking the scope and scale! What IMUGENE has achieved in les than 4 years is staggering, if you understand Biotech. Yuman FONG definitely thinks the achievements o PH and LC are amazing, he keeps telling us this. Like dog years , Biotech years are about 5 human years to One biotech year. This will get IMU a spot in the Guinness Book of records. And CEO LC will win the Biotech CEO of the century with this achievement.

For new investors to Biotech, there is a stage in the lifecycle of. Biotech that’s called the “Valley of Death”. All start up Bios must pass through the valley of death before success. If you have read Steini’s post ripping into your Chairman Paul Hopper for the non-performance of his other ASX listed companies CHM and RAD, you will see the effects of travelling thru the valley of death. Unfortunately it’s a real trap for investors. A very high percentage of Biotech’ lose considerable value in the years after list whilst they travel thru the valley of death, costing early holders considerable money, because the punters lose patience and sell. Often leaving pissed off because of the endless cap raises at lower and lower share prices to fund the ongoing development. Then one day in less tha 10% of companies they see huge success and make massive money. Unfortunately for Steini he bought into both CHM and RAD far too early.

It the great news for IMU shareholders is that by November 2023 we will be on the other side of the valley of death and on our way to some serious big rewards. We got two amazing bits of news just this week., We cleared cohort 3 of the IT Monotherapy arm of the Vaxinia Mast Trial with the clear statement from our CEO that she is can’t wait to share the results with us. And secondly that we now own the front runner in the allergenic CD 19 CarT space. And it’s ready and FDA supported for Registrational Trials. IMU is fully funded to complete the development and Breakthrough Approvals phase of the first and only UNIVERSAL VACCINE AGAINST ALL CANCERS.

Just read that last sentence again. And think was all this worth a 6.5% dilution considering the massive uplift in valuation we got handed this week. It’s very important to spend time analysing the underlying value of the assets and IP that you Biotech Investment owns. Making decisions based on the out of control emotions some people get from watching the SP all day will end in tears for certain. Remember this is the hardest sector of the stock market to make successful investments, If you don’t have the money, experience and emotional resilience that’s required YOU WILL LOSE MONEY.. Stop blaming the Chairman for the mistakes YOU made.

Expand

Paul and Lesley

Thanks so much for the update, could you please do the updates on the ASX / company formats?

Thanks

XR

No.	Vol.	Price($)
5	1925982	4.8¢

No.

Vol.

Price($)

1925982

4.8¢

Price($)	Vol.	No.
4.9¢	3452098	12

Price($)

Vol.

No.

4.9¢

3452098

No.	Vol.	Price($)
5	1925982	0.048
33	4297134	0.047
47	3841303	0.046
53	6064000	0.045
11	2329545	0.044

No.

Vol.

Price($)

1925982

0.048

4297134

0.047

3841303

0.046

6064000

0.045

2329545

0.044

Price($)	Vol.	No.
0.049	2620667	8
0.050	2639213	14
0.051	6431004	11
0.052	2071350	7
0.053	418882	5

Price($)

Vol.

No.

0.049

2620667

0.050

2639213

0.051

6431004

0.052

2071350

0.053

418882

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$2.298M	47.86M

Paul and Lesley Thanks so much for the update, could you please...

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Paul and Lesley Thanks so much for the update, could you please...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

The market's shrugged at China's stimulus measures all year. Why is this one different?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News